Literature DB >> 32418182

An Analysis of Racial and Ethnic Backgrounds Within the CASiRe International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research.

Andrew D Campbell1,2, Raffaella Colombatti3, Biree Andemariam4, Crawford Strunk5, Immacolata Tartaglione6, Connie M Piccone7, Deepa Manwani8, Eugenia Vicky Asare9,10, Donna Boruchov11, Fatimah Farooq12, Rebekah Urbonya12, Gifty Dankwah Boatemaa13, Silverio Perrotta6, Laura Sainati3, Angela Rivers14, Sudha Rao15, William Zempsky11, Fredericka Sey9, Catherine Segbefia15, Baba Inusa16, Charles Antwi-Boasiako13.   

Abstract

Millions are affected by sickle cell disease (SCD) worldwide with the greatest burden in sub-Saharan Africa. While its origin lies historically within the malaria belt, ongoing changes in migration patterns have shifted the burden of disease resulting in a global public health concern. We created the Consortium for the Advancement of Sickle Cell Research (CASiRe) to understand the different phenotypes of SCD across 4 countries (USA, UK, Italy, and Ghana). Here, we report the multi-generational ethnic and racial background of 877 SCD patients recruited in Ghana (n = 365, 41.6%), the USA (n = 254, 29%), Italy (n = 81, 9.2%), and the UK (n = 177, 20.2%). West Africa (including Benin Gulf) (N = 556, 63.4%) was the most common geographic region of origin, followed by North America (N = 184, 21%), Caribbean (N = 51, 5.8%), Europe (N = 27, 3.1%), Central Africa (N = 24, 2.7%), and West Africa (excluding Benin Gulf) (N = 21, 2.4%). SCD patients in Europe were primarily West African (73%), European (10%), Caribbean (8%), and Central African (8%). In the USA, patients were largely African American (71%), Caribbean (13%), or West African (10%). Most subjects identified themselves as Black or African American; the European cohort had the largest group of Caucasian SCD patients (8%), including 21% of the Italian patients. This is the first report of a comprehensive analysis of ethnicity within an international, transcontinental group of SCD patients. The diverse ethnic backgrounds observed in our cohort raises the possibility that genetic and environmental heterogeneity within each SCD population subgroup can affect the clinical phenotype and research outcomes.

Entities:  

Keywords:  Ethnicity; International; Phenotype; Race; Sickle cell

Mesh:

Year:  2020        PMID: 32418182      PMCID: PMC7669607          DOI: 10.1007/s40615-020-00762-2

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  32 in total

1.  Generation of integration-free iPS cell lines from three sickle cell disease patients from the state of Bahia, Brazil.

Authors:  Gabriele Louise Soares Martins; Bruno Diaz Paredes; Carine Machado Azevedo; Gabriela Louise De Almeida Sampaio; Carolina Kymie Vasques Nonaka; Bruno Raphael Ribeiro Cavalcante; Katia Nunes Da Silva; Ciro Silveira E Pereira; Milena Botelho Pereira Soares; Ricardo Ribeiro Dos Santos; Bruno Solano De Freitas Souza
Journal:  Stem Cell Res       Date:  2018-09-25       Impact factor: 2.020

2.  Sickle Cell Disease.

Authors:  Frédéric B Piel; Martin H Steinberg; David C Rees
Journal:  N Engl J Med       Date:  2017-07-20       Impact factor: 91.245

3.  Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia.

Authors:  Julie Kanter; Lori E Heath; Jack Knorr; E Tsiri Agbenyega; Raffaella Colombatti; Carlton Dampier; Hoda Hassab; Deepa Manwani; Nancy Robitaille; Patricia B Brown; Joseph A Jakubowski; Suqin Yao; Carolyn Hoppe
Journal:  Br J Haematol       Date:  2018-04-20       Impact factor: 6.998

4.  A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.

Authors:  Elliott Vichinsky; Carolyn C Hoppe; Kenneth I Ataga; Russell E Ware; Videlis Nduba; Amal El-Beshlawy; Hoda Hassab; Maureen M Achebe; Salam Alkindi; R Clark Brown; David L Diuguid; Paul Telfer; Dimitris A Tsitsikas; Ashraf Elghandour; Victor R Gordeuk; Julie Kanter; Miguel R Abboud; Joshua Lehrer-Graiwer; Margaret Tonda; Allison Intondi; Barbara Tong; Jo Howard
Journal:  N Engl J Med       Date:  2019-06-14       Impact factor: 91.245

Review 5.  Differences in the clinical and genotypic presentation of sickle cell disease around the world.

Authors:  Santosh L Saraf; Robert E Molokie; Mehdi Nouraie; Craig A Sable; Lori Luchtman-Jones; Gregory J Ensing; Andrew D Campbell; Sohail R Rana; Xiao M Niu; Roberto F Machado; Mark T Gladwin; Victor R Gordeuk
Journal:  Paediatr Respir Rev       Date:  2013-11-15       Impact factor: 2.726

6.  A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.

Authors:  Matthew M Heeney; Carolyn C Hoppe; Miguel R Abboud; Baba Inusa; Julie Kanter; Bernhards Ogutu; Patricia B Brown; Lori E Heath; Joseph A Jakubowski; Chunmei Zhou; Dmitry Zamoryakhin; Tsiri Agbenyega; Raffaella Colombatti; Hoda M Hassab; Videlis N Nduba; Janet N Oyieko; Nancy Robitaille; Catherine I Segbefia; David C Rees
Journal:  N Engl J Med       Date:  2015-12-08       Impact factor: 91.245

7.  New variants in beta globin gene among the Palestinian refugees with sickle cell disease in Lebanon.

Authors:  Esraa Y Moussa; Noura M Yassine; Jamilah M Borjac
Journal:  Saudi Med J       Date:  2018-12       Impact factor: 1.484

8.  A systematic literature review on the European, African and Amerindian genetic ancestry components on Brazilian health outcomes.

Authors:  Fabiana Dos Santos Carolino Firmo Pereira; Raphael Mendonça Guimarães; Alexandre Ramos Lucidi; Doralina Guimarães Brum; Carmen Lucia Antão Paiva; Regina Maria Papais Alvarenga
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

9.  Interethnic diversity of the CD209 (rs4804803) gene promoter polymorphism in African but not American sickle cell disease.

Authors:  Jenelle A Noble; Kimberley C Duru; Aldiouma Guindo; Li Yi; Ikhide G Imumorin; Dapa A Diallo; Bolaji N Thomas
Journal:  PeerJ       Date:  2015-02-24       Impact factor: 2.984

10.  Comparison of patients from Nigeria and the USA highlights modifiable risk factors for sickle cell anemia complications.

Authors:  Titilola S Akingbola; Bamidele O Tayo; Babatunde Salako; Jennifer E Layden; Lewis L Hsu; Richard S Cooper; Victor R Gordeuk; Santosh L Saraf
Journal:  Hemoglobin       Date:  2014-06-18       Impact factor: 0.849

View more
  4 in total

1.  Confronting Racism in All Forms of Pain Research: Reframing Study Designs.

Authors:  Janelle E Letzen; Vani A Mathur; Mary R Janevic; Michael D Burton; Anna M Hood; Calia A Morais; Staja Q Booker; Claudia M Campbell; Edwin N Aroke; Burel R Goodin; Lisa C Campbell; Ericka N Merriwether
Journal:  J Pain       Date:  2022-02-26       Impact factor: 5.383

2.  Global geographic differences in healthcare utilization for sickle cell disease pain crises in the CASiRe cohort.

Authors:  Crawford Strunk; Immacolata Tartaglione; Connie M Piccone; Raffaella Colombatti; Biree Andemariam; Deepa Manwani; Ashya Smith; Haikel Haile; Esther Kim; Samuel Wilson; Eugenia Vicky Asare; Angela Rivers; Fatimah Farooq; Rebekah Urbonya; Donna Boruchov; Gifty Dankwah Boatemaa; Silverio Perrotta; Ivy Ekem; Laura Sainati; Sudha Rao; William Zempsky; Fredericka Sey; Charles Antwi-Boasiako; Catherine Segbefia; Baba Inusa; Andrew D Campbell
Journal:  Blood Cells Mol Dis       Date:  2021-09-21       Impact factor: 3.039

3.  Distribution of HbS Allele and Haplotypes in a Multi-Ethnic Population of Guinea Bissau, West Africa: Implications for Public Health Screening.

Authors:  Maddalena Martella; Mimma Campeggio; Gift Pulè; Ambroise Wonkam; Federica Menzato; Vania Munaretto; Giampietro Viola; Sabado P Da Costa; Giulia Reggiani; Antonia Araujo; Dionisio Cumbà; Giuseppe Liotta; Laura Sainati; Fabio Riccardi; Raffaella Colombatti
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.569

Review 4.  Sickle cell trait and the potential risk of severe coronavirus disease 2019-A mini-review.

Authors:  Tawakalitu Abosede Kehinde; Mayowa Azeez Osundiji
Journal:  Eur J Haematol       Date:  2020-07-14       Impact factor: 3.674

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.